|
case study
Bayer rips up its spreadsheets after Information Systems review
IS strategy makes progress with consultancy from Scimcon
Bayer
Pharmaceutical’s biotechnology division in
Berkeley California analyses thousands of protein samples each
year in its quest to develop medication to battle
life-threatening illnesses such as cancer and pulmonary
diseases. The
biotechnology site helps the development of new drugs through
this protein research and analysis. If the lab is to do this as
efficiently as possible, it’s crucial that the research data
is recorded accurately and managed effectively.
To
harness the wealth of information now available for drug
discovery, Bayer Biotech has embarked upon a five-year plan to
redesign its information management to support the research and
development processes more effectively.
Scientific
information management consultancy Scimcon has been crucial to
Bayer Biotech’s development of an integrated information
management strategy. The companies began a partnership in April 2001, since when
Scimcon has provided a strategic review of information
management and worked with Bayer Biotech to develop a new system
to track its drug development process.
Prior
to this strategic review, Bayer Biotech’s data and derivative
works supporting the drug discovery process had been stored in a
mixture of electronic systems, paper based records, and on
Microsoft Word, Excel and PowerPoint applications.
There was no central system through which it could store
all of the information required to manage the complex and
integrated R&D process.
This
meant that data required by project teams was separated into
disparate islandsmaking it difficult to make efficient
decisions. Bayer
Biotech also had a LIMS (Laboratory Information Management
System) product which it felt was not supporting the business
effectively.
Recognising
that it needed external expertise to overcome these hurdles,
Bayer asked Scimcon to review its information management
requirements.
Ken
Kupfer, Head of Biotechnology Scientific Informatics at
Bayer Corporation, explains the reasons for selecting Scimcon as
a consultancy partner:
“Scimcon
has a solid track record of practical experience in lab IS
management, as well as the pre-requisite understanding of the
regulatory and business requirements upon us. We’d heard good things about Scimcon, and the first job
they undertook on our behalf proved further that we could trust
them to deliver.”
Scimcon
started by undertaking a thorough review of Bayer Biotech’s
information management processes in April 2001. It
put forward a set of strategic recommendations, which included
the complete reorganisation of Bayer’s Biotech’s information
strategy and processes.
Ken
Kupfer, again:
“Scimcon’s
experience in lab information management means that it
understands user requirements and knows how best to approach IS
strategy and system management. Scimcon provided us with a
realistic view of what it would take to implement a complex
information management system and has mapped out our business
needs and ensured that our IS strategy matches those
requirements.”
A
central plank of the strategic recommendations made by Scimcon
was the need to develop a new candidate tracking system. This
is a system to track status and process information on novel
drug candidates throughout the stages of their research and
development.
Scimcon
advised that, rather than invest in entirely new software, it
could develop the existing LIMS product that Bayer Biotech had
already purchased..
To date, this system had not been meeting the lab’s IS
needs. So in June 2001 Scimcon began to reconfigure the existing
software into a new system that could manage the candidate
tracking system more efficiently and accurately.
The systems development work was completed on time and to
budget in December 2001 and now serves 270 people comprising 30
individual lab units.
The
IS strategy review and new tracking system have enabled Bayer to
streamline and simplify its data management processes, making
these far easier for users to handle and understand.
Ken
Kupfer explains the benefit:
“Two
years ago, our concept of information management was
bioinformatics. But now, thanks to Scimcon, we see the value of
an integrated approach to information management that supports
our entire R&D process. There has been an immediate business
improvementin that vital information supporting the drug
discovery process is now stored in one central, automated
system, which has replaced the mismash of Word and Excel
documents which we’ve since been able to rip up and discard.”
However,
the work undertaken by Scimcon to date is just one facet of the
much wider-ranging five-year programme to improveBayer Biotech’s
information management infrastructure. Bayer Biotech still
has more work to do before optimum efficiency is attained
throughout the biotechnology division. It intends to continue
working with Scimcon to achieve this.
Ken
Kupfer concludes:
“Scimcon’s
work has been integral to improving our IS processes and without
it the progress that we have made thus far would not have been
possible. We
do still have a long way to go yet, and we expect Scimcon to
remain a solid partner that we continue to depend on.”
|